EGFR (also known as ErbB1/HER1) is commonly upregulated in several cancer types including pancreatic cancer, and thus EGFR-targeted therapies have been developed, including monoclonal antibodies against the extracellular domain of EGFR and tyrosine kinase inhibitors (TKIs) [70,79]. This evidence concerns the gene EGFR and familial pancreatic carcinoma.